JEMMDX LIMITED

JEMMDX LIMITED is a United Kingdom-based medical and clinical affairs consultancy focused on enabling the commercialisation of patient-centric medical diagnostics, medical devices and FemTech products. Registered as a company in Bedford, United Kingdom, the firm positions itself as a specialist advisory partner for organisations that need to bring diagnostic and device innovations through clinical, regulatory and market-access pathways. Its website describes a team with more than 25 years of experience and a track record of launching over 20 in-vitro diagnostic (IVD) products globally. The consultancy's core services are organised around four pillars: product and market access, regulatory and clinical strategy, medical communications, and stakeholder engagement. Under product and market access, JEMMDX offers landscape analysis, Innovative MedTech Pathways, scientific partnerships, NHS access analysis and product roadmaps. Its regulatory and clinical work covers clinical performance and usability/human factors trials, IVDR gap analysis and remediation, submission support for IVDR, UKCA, FDA and MHRA, post-launch evaluations, quality and regulatory compliance training, and scientific validity and state-of-the-art assessments. Medical communications services include scientific narratives through to journal publication, product key messages, white papers, cost-effectiveness pathway analysis, conference symposia and CME programmes. Stakeholder engagement spans advisory boards, grant applications, KOL mapping and engagement strategy, access to global leading hospitals and universities, investor pitch support, and NIHR/AHSN/DHSC stakeholder discussions. The firm is led by named principals with deep industry backgrounds. Dr Jayne Ellis is described as a medical and clinical affairs executive with more than 25 years of industry leadership in global medical and clinical affairs, product launch and market development across diagnostics, FemTech and consumer healthcare, with prior roles at Unilever, SPD, Alere/Abbott and LumiraDx; she also serves as a Scientific Advisor on antimicrobial resistance (AMR) to BIVDA and UNICEF. Marcia McNicol is described as a quality and regulatory affairs executive with more than 25 years of experience leading medical device and IVD work in global regulated markets, including at J&J, Alere/Abbott and LumiraDx. The company highlights the combined experience of its team as exceeding 50 years across all aspects of diagnostic and device development and launch. JEMMDX operates in the specialised niche where clinical evidence, regulatory compliance and commercial strategy intersect. Its clients are typically diagnostic, device and FemTech companies seeking to navigate the increasingly complex European and UK regulatory environment, including the In Vitro Diagnostic Regulation (IVDR) and UKCA marking. The company publishes case studies and articles on bringing diagnostic products to market and invites collaboration through its website. As a private limited company, it does not disclose public financial statements, and its exact founding date is not stated in the available evidence.

JEMMDX LIMITED is a United Kingdom company registered in Bedford, as recorded in public company data. The available evidence does not state a precise founding year, but the firm presents itself as a consultancy built on the combined experience of its principals, who between them bring more than 50 years in diagnostics, medical devices and FemTech. Dr Jayne Ellis and Marcia McNicol, the named leaders, each have over 25 years of industry experience, with backgrounds spanning Unilever, SPD, Alere/Abbott, LumiraDx and J&J. Their careers cover global medical and clinical affairs, product launch, market development, quality and regulatory affairs for medical devices and in-vitro diagnostics. The company's formation appears to have been driven by the growing complexity of the European and UK regulatory landscape, particularly the In Vitro Diagnostic Regulation (IVDR) and UKCA marking, which created demand for specialist advisory services. JEMMDX positions itself as a partner that can guide diagnostic, device and FemTech companies through clinical trials, regulatory submissions and market access. Its website notes experience launching over 20 IVD products globally, which underpins its consulting offer. JEMMDX organises its services into four core areas: product and market access; regulatory and clinical; medical communications; and stakeholder engagement. It publishes case studies and articles on bringing diagnostic products to market, and it invites clients to collaborate. The company operates worldwide, with particular emphasis on the UK and European markets, including NHS access analysis and engagement with NIHR, AHSN and DHSC stakeholders. As a private limited company, it does not publish public financial results, and no major corporate events such as acquisitions or listings are documented in the available evidence.

• Company registered in Bedford, United Kingdom (date not specified in evidence)

• Team accumulates 25+ years of experience and launches over 20 IVD products globally (per website)

Specialist consultancy enabling commercialisation of patient-centric diagnostics, devices and FemTech, with deep expertise in clinical, regulatory and market-access pathways.

• Product and market access consulting

  Landscape analysis, Innovative MedTech Pathways, scientific partnerships, NHS access analysis, product roadmap.

• Regulatory and clinical consulting

  Clinical performance and usability/human factors trials, IVDR gap analysis and remediation, submission support (IVDR, UKCA, FDA, MHRA), post-launch evaluations, quality and regulatory compliance training, scientific validity and SOTA.

• Medical communications

  Scientific narrative to journal publication, product key messages, white papers, cost-effectiveness pathway analysis, conference symposia and CME programmes.

• Stakeholder engagement

  Advisory boards, grant applications, KOL mapping and engagement strategy, access to global leading hospitals and universities, investor pitch support, NIHR/AHSN/DHSC stakeholder discussions.

1. 1Medical Business Strategy Consultants Worldwide | JEMMDxjemmdx.com
2. 2Stake Holder Engagement & Medical Publications | JEMMDxjemmdx.com
3. 3Medical Consultancy & Publications Worldwide | JEMMDxjemmdx.com
4. 4JEMMDX LIMITED (United Kingdom) - Wikidatawikidata.org